

ABSTRACT OF THE DISCLOSURE

The present invention is directed towards a method of potentiating the anti-growth effects of type I interferon (IFN) on cells in a target cell population comprising increasing the number of functional IFNAR2c receptors on the surface of modified cells within the target cell population and then exposing the modified cells to a therapeutically effective amount of a type I IFN or by exposure to endogenously produced IFN.